EP1155016A1 - Processus de production de solvate acetonique d'hydrochlorure de paroxetine - Google Patents

Processus de production de solvate acetonique d'hydrochlorure de paroxetine

Info

Publication number
EP1155016A1
EP1155016A1 EP99973028A EP99973028A EP1155016A1 EP 1155016 A1 EP1155016 A1 EP 1155016A1 EP 99973028 A EP99973028 A EP 99973028A EP 99973028 A EP99973028 A EP 99973028A EP 1155016 A1 EP1155016 A1 EP 1155016A1
Authority
EP
European Patent Office
Prior art keywords
paroxetine hydrochloride
acetone solvate
crystalline
microns
acetone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99973028A
Other languages
German (de)
English (en)
Inventor
Andrew Simon Smithkline Beecham Pharm. Craig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of EP1155016A1 publication Critical patent/EP1155016A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Definitions

  • the present invention relates to a process for the preparation of a pharmaceutically active compound and intermediates thereof, and to the use of the active compound in therapy.
  • this invention is concerned with a new process for the preparation of paroxetine chloride acetone solvate and its use to prepare a crystalline anhydrate form of paroxetine hydrochloride.
  • Paroxetine hydrochloride has been described in the literature as a crystalline hemihydrate (see EP-A-0223403 of Beecham Group) and as various crystalline anhydrate forms (see WO96/24595 of SmithKline Beecham).
  • WO96/24595 describes the preparation of paroxetine hydrochloride acetone solvate which is a useful intermediate for the preparation of paroxetine hydrochloride anhydrate Form A.
  • paroxetine hydrochloride acetone solvate When prepared conventionally by crystallisation from anhydrous acetone, paroxetine hydrochloride acetone solvate has poor stirring properties, and is difficult to isolate, wash, and dry.
  • This invention provides processes for the preparation of paroxetine hydrochloride acetone solvate in a form which is more easily desolvated than paroxetine hydrochloride acetone solvate prepared in a conventional manner, and hence more suitable for commercial manufacturing processes.
  • a process for preparing crystalline paroxetine hydrochloride acetone solvate which comprises providing a solution of paroxetine hydrochloride in acetone, adding to the solution a habit modifier compound, and crystallising paroxetine hydrochloride acetone solvate from the modified solution.
  • Suitable habit modifying compounds are selected from those compounds that are ionic or readily ionisable and are soluble in acetone.
  • the addition of the indicated habit modifier compound to the solution modifies the habit of the resultant crystals to a form which allows for convenient stirring, filtering and washing on a manufacturing scale, and more effective de-solvation of the crystals.
  • a suitable concentration of paroxetine hydrochloride in acetone is one part in between 10 and 50 volumes of acetone, preferably between 15 and 40 volumes, and more preferably between 20 and 30 volumes.
  • the acetone is anhydrous to suppress formation of paroxetine hydrochloride hemihydrate.
  • Suitable procedures for preparing paroxetine hydrochloride for dissolution in acetone for use in the process of this invention include those mentioned in US Patents 4,009,196; 4,721,723; 4,902,801; 4,861,893 and 5,039,803.
  • Suitable habit modifiers are carboxylic acids, preferably acetic acid, and amine salts, particularly hydrochloride or acetate salts, for example diethylamine hydrochloride or ammonium acetate.
  • the amount of carboxylic acid habit modifier used is suitably from 1 to 20% of the solvent volume, preferably from 1 to 10%.
  • a suitable amount of amine salt habit modifier is in the range 5-25 mole %, preferably 10- 20 mole %.
  • Crystallisation may be initiated by conventional procedures such as cooling a heated solution, or removing solvent by evaporation or heating. It may be advantageous to add seeds of crystalline paroxetine hydrochloride acetone solvate prepared by the procedure of this invention or by the procedure of WO 96/24595.
  • the crystalline paroxetine hydrochloride acetone solvate of modified crystal habit obtainable by the process of this invention is a different crystalline form from the previously known product. This novel product forms another aspect of this invention.
  • Paroxetine hydrochloride acetone solvate crystals prepared conventionally are large and long, typically with most of the material in the form of crystals in excess of 300 microns in length, with a length-to-width ratio in excess of 40:1, and a volume of 20,000 cubic microns or more.
  • most of the material is in crystals less than 100 microns long, preferably below 75 microns, and more preferably below 50 microns, and with a length-to-width ratio below 20:1, preferably below 15:1 and more preferably below 10:1, and with a volume below 5,000 cubic microns, preferably below 2,500 cubic microns and more preferably below 1,000 cubic microns.
  • the product of this invention may have either one, two or all three of these desirable characteristics.
  • paroxetine hydrochloride acetone solvate of modified habit in which the mean distance between crystal facets characterised by the Miller indices (0, 1, 0) and (0, 1, 0) in a monoclinic crystal system, P2, space group is minimised, and is preferably below 100 microns.
  • paroxetine hydrochloride acetone solvate with these characteristics may be processed and desolvated more easily than conventionally produced paroxetine hydrochloride acetone solvate.
  • the present invention provides a process for preparing a crystalline anhydrate of paroxetine hydrochloride by heating crystalline acetone solvate obtainable by the process of this invention to remove bound acetone.
  • Desolvation is conveniently carried out by heating in an oven, preferably in vacuo, suitably at a temperature of about 50°C.
  • the resultant anhydrate desirably contains less than 4% of acetone, preferably less than 2%, more preferably less than 1%, and most preferably less than 0.5%.
  • the crystalline anhydrate is the Form A anhydrate of paroxetine hydrochloride.
  • the crystalline paroxetine hydrochloride anhydrate obtainable by this invention may be used in therapy in formulations described in EP-A-0223403 or WO 96/00477.
  • paroxetine hydrochloride anhydrate of this invention include treatment of: alcoholism, anxiety, depression, obsessive compulsive disorder (OCD), panic disorder, chronic pain, obesity, senile dementia, migraine, bulimia, anorexia, social phobia, pre-menstrual syndrome (PMS), adolescent depression, trichotillomania, dysthymia, and substance abuse, referred to below as "the disorders”.
  • OCD obsessive compulsive disorder
  • PMS pre-menstrual syndrome
  • adolescent depression trichotillomania
  • dysthymia substance abuse
  • the anhydrate obtainable by the present invention is applied to the treatment of depression, OCD and panic.
  • the composition is usually presented as a unit dose composition containing from 1 to 200mg of active ingredient calculated on a free base basis, more usually from 5 to lOOmg, for example 10 to 50mg such as 10, 12.5, 15, 20, 25, 30 or 40mg by a human patient. Most preferably unit doses contain 20mg of active ingredient calculated on a free base basis. Such a composition is normally taken from 1 to 6 times daily, for example 2, 3 or 4 times daily so that the total amount of active agent administered is within the range 5 to 400mg of active ingredient calculated on a free base basis. Most preferably the unit dose is taken once a day.
  • Preferred unit dosage forms include tablets or capsules, including formulations adapted for controlled or delayed release.
  • compositions of this invention may be formulated by conventional methods of admixture such as blending, filling and compressing.
  • Suitable carriers for use in this invention include a diluent, a binder, a disintegrant, a colouring agent, a flavouring agent and/or preservative. These agents may be utilized in conventional manner, for example in a manner similar to that already used for marketed anti-depressant agents.
  • compositions include those described EP-B-0223403, and US 4,007,196 in which the anhydrate product of the present invention may be used as the active ingredient.
  • the present invention also provides: a pharmaceutical composition for treatment or prophylaxis of the disorders comprising paroxetine hydrochloride anhydrate obtainable by this invention and a pharmaceutically acceptable carrier;
  • paroxetine hydrochloride anhydrate obtainable by this invention to manufacture a medicament for the treatment or prophylaxis of the disorders
  • a method of treating the disorders which comprises administering an effective or prophylactic amount of paroxetine hydrochloride anhydrate obtainable by this invention to a person suffering from one or more of the disorders.
  • the invention is illustrated by the following Examples.
  • drying has been carried out under standardised conditions for the purpose of comparison.
  • Conventionally prepared paroxetine hydrochloride acetone solvate contains approximately 6% acetone under these drying conditions.
  • Paroxetine hydrochloride with lower residual acetone can be obtained by increasing the drying time or temperature.
  • paroxetine hydrochloride 10 g
  • acetone 300 ml
  • diethylamine hydrochloride 0.5g
  • the reaction mixture is slowly cooled to room temperature with stirring.
  • the resulting white crystalline solid is filtered, washed with acetone and dried under vacuum at 45 °C for 20 hours to give paroxetine hydrochloride, containing approximately 1.5% acetone by weight.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Dans cette invention, on obtient un solvate acétonique d'hydrochlorure de paroxétine cristallin présentant une caractéristique modifiée plus facilement désolvatée pour former l'anhydre, en le cristallisant à partir d'une solution d'hydrochlorure de paroxétine en présence d'acétone, solution à laquelle on ajoute un composé de modification de caractéristique. On obtient la forme A d'anhydre en chauffant le solvate cristallin à caractéristique modifiée dans une étuve sous vide. Les modificateurs de caractéristiques appropriés sont les acides carboxyliques et les sels d'amine.
EP99973028A 1998-11-30 1999-11-30 Processus de production de solvate acetonique d'hydrochlorure de paroxetine Withdrawn EP1155016A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9826178 1998-11-30
GBGB9826178.7A GB9826178D0 (en) 1998-11-30 1998-11-30 Novel process
PCT/GB1999/003996 WO2000032595A1 (fr) 1998-11-30 1999-11-30 Processus de production de solvate acetonique d'hydrochlorure de paroxetine

Publications (1)

Publication Number Publication Date
EP1155016A1 true EP1155016A1 (fr) 2001-11-21

Family

ID=10843290

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99973028A Withdrawn EP1155016A1 (fr) 1998-11-30 1999-11-30 Processus de production de solvate acetonique d'hydrochlorure de paroxetine

Country Status (5)

Country Link
EP (1) EP1155016A1 (fr)
JP (1) JP2002531453A (fr)
AU (1) AU1398100A (fr)
GB (1) GB9826178D0 (fr)
WO (1) WO2000032595A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923439D0 (en) * 1999-10-04 1999-12-08 Smithkline Beecham Plc Novel process
GB9923445D0 (en) * 1999-10-04 1999-12-08 Smithkline Beecham Plc Novel process

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
EP0223403B1 (fr) * 1985-10-25 1993-08-04 Beecham Group Plc Dérivé de pipéridine, sa préparation et son utilisation comme médicament
SK283608B6 (sk) * 1995-02-06 2003-10-07 Smithkline Beecham Plc Bezvodý hydrochlorid paroxetínu, spôsob jeho výroby a použitie
EP1384711A1 (fr) * 1996-06-13 2004-01-28 SUMIKA FINE CHEMICALS Co., Ltd. Résolution optique d'un dérivé pipéridine
HU221921B1 (hu) * 1996-07-08 2003-02-28 Richter Gedeon Vegyészeti Gyár Rt. N-benzil-piperidin- és tetrahidropiridinszármazékok és eljárás azok előállítására

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0032595A1 *

Also Published As

Publication number Publication date
GB9826178D0 (en) 1999-01-20
AU1398100A (en) 2000-06-19
WO2000032595A1 (fr) 2000-06-08
JP2002531453A (ja) 2002-09-24

Similar Documents

Publication Publication Date Title
EP0808314B1 (fr) Formes de l'hydrochlorure de paroxetine
JP2002503248A (ja) ４−フェニルピペリジン化合物
EP1414454A1 (fr) Glycyrrhyzinate de paroxetine
EP1137636A1 (fr) Procede de preparation de maleate de paroxetine
WO2000035910A1 (fr) Derive paroxetinique
EP1155016A1 (fr) Processus de production de solvate acetonique d'hydrochlorure de paroxetine
WO1999052901A1 (fr) Maleate de paroxetine
WO2000032592A1 (fr) Procede de fabrication d'hydrochlorure de paroxetine
EP1135383B1 (fr) Solvates de paroxetine propan-2-ol melanges
JP2001526288A (ja) パロキセチン塩酸塩の製法
US20020028942A1 (en) Novel process and compound
WO2001012623A1 (fr) Procede de preparation d'hydrochlorure de paroxetine anhydre
SK13622000A3 (sk) Kryštalická forma paroxetínu, farmaceutický prostriedok a použitie
WO2000078752A1 (fr) Procede de production de chlorhydrate de paroxetine
WO2001025201A1 (fr) Procede de preparation de produit intermediaire de paroxetine
WO2000032591A1 (fr) Procede de fabrication d'hydrochlorure de paroxetine
WO2000032596A1 (fr) Sels amines de paroxetine
WO2001025230A1 (fr) Procede de preparation de solvate acetonique d'hydrochlorure de paroxetine
BG104973A (bg) Пароксетин 10-камфорсулфонат за лечение на cns заболявания
CZ20003343A3 (cs) Krystalická forma paroxetinu
WO2001014369A2 (fr) Nouveau procede
MXPA00006040A (en) Process for the preparation of paroxetine hydrochloride
WO2001025231A1 (fr) Preparation d'un solvate cetonique de chlorhydrate de paroxetine
CZ20003722A3 (cs) Maleat paroxetinu
EP1140910A1 (fr) Procede de preparation d'un acetate de paroxetine ou d'analogues de paroxetine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010809

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SMITHKLINE BEECHAM PLC

17Q First examination report despatched

Effective date: 20070201

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070601